court-istock-451264349-tomloel-

tomloel / iStockphoto.com

3 April 2017Americas

Four of Acorda’s Ampyra patents invalidated

A Delaware district court has invalidated four patents owned by Acorda Therapeutics after the company and Alkermes Pharma Ireland alleged that Apotex, Mylan, Roxane Laboratories and Teva infringed them.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

BIO and PhRMA back Acorda in patent appeal

17 August 2017 The Biotechnology Industry Organization and the Pharmaceutical Research and Manufacturers of America, two trade groups representing US pharmaceutical companies, have backed Acorda in an appeal to the US Court of Appeals for the Federal Circuit.

Victory for Mylan and Teva as appeals court affirms invalidations

12 September 2018 Generic drug makers Mylan and Teva were afforded victory earlier this week when the US Court of Appeals for the Federal Circuit affirmed the invalidation of four patents owned by biotech company Acorda Therapeutics.

More on this story

BIO and PhRMA back Acorda in patent appeal

17 August 2017 The Biotechnology Industry Organization and the Pharmaceutical Research and Manufacturers of America, two trade groups representing US pharmaceutical companies, have backed Acorda in an appeal to the US Court of Appeals for the Federal Circuit.

Victory for Mylan and Teva as appeals court affirms invalidations

12 September 2018 Generic drug makers Mylan and Teva were afforded victory earlier this week when the US Court of Appeals for the Federal Circuit affirmed the invalidation of four patents owned by biotech company Acorda Therapeutics.

More on this story

BIO and PhRMA back Acorda in patent appeal

17 August 2017 The Biotechnology Industry Organization and the Pharmaceutical Research and Manufacturers of America, two trade groups representing US pharmaceutical companies, have backed Acorda in an appeal to the US Court of Appeals for the Federal Circuit.

Victory for Mylan and Teva as appeals court affirms invalidations

12 September 2018 Generic drug makers Mylan and Teva were afforded victory earlier this week when the US Court of Appeals for the Federal Circuit affirmed the invalidation of four patents owned by biotech company Acorda Therapeutics.

More features

Chinese biotech takes out US rival’s nucleic acid patent at PTAB

Lewis Roca promotes tech expert to managing partner

Panitch Schwarze brings in molecular biologist

US targets ‘product hopping’ with biologic litigation curbs

UPC confirms validity of Edwards Lifesciences heart valve tech patent

ITC concludes row over biotech lab equipment between US and German rivals

UKIPO launches ‘revolutionary’ patent filing and AI tool

USPTO clarifies AI's role in patent eligibility